Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial

EBioMedicine. 2015 Nov 5;2(12):2024-36. doi: 10.1016/j.ebiom.2015.11.003. eCollection 2015 Dec.


Background: Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that causes a deficit of pancreatic islet β cells. The complexities of overcoming autoimmunity in T1D have contributed to the challenges the research community faces when devising successful treatments with conventional immune therapies. Overcoming autoimmune T cell memory represents one of the key hurdles.

Methods: In this open-label, phase 1/phase 2 study, Caucasian T1D patients (N = 15) received two treatments with the Stem Cell Educator (SCE) therapy, an approach that uses human multipotent cord blood-derived multipotent stem cells (CB-SCs). SCE therapy involves a closed-loop system that briefly treats the patient's lymphocytes with CB-SCs in vitro and returns the "educated" lymphocytes (but not the CB-SCs) into the patient's blood circulation. This study is registered with, NCT01350219.

Findings: Clinical data demonstrated that SCE therapy was well tolerated in all subjects. The percentage of naïve CD4(+) T cells was significantly increased at 26 weeks and maintained through the final follow-up at 56 weeks. The percentage of CD4(+) central memory T cells (TCM) was markedly and constantly increased at 18 weeks. Both CD4(+) effector memory T cells (TEM) and CD8(+) TEM cells were considerably decreased at 18 weeks and 26 weeks respectively. Additional clinical data demonstrated the modulation of C-C chemokine receptor 7 (CCR7) expressions on naïve T, TCM, and TEM cells. Following two treatments with SCE therapy, islet β-cell function was improved and maintained in individuals with residual β-cell function, but not in those without residual β-cell function.

Interpretation: Current clinical data demonstrated the safety and efficacy of SCE therapy in immune modulation. SCE therapy provides lasting reversal of autoimmune memory that could improve islet β-cell function in Caucasian subjects.

Funding: Obra Social "La Caixa", Instituto de Salud Carlos III, Red de Investigación Renal, European Union FEDER Funds, Principado de Asturias, FICYT, and Hackensack University Medical Center Foundation.

Keywords: AIRE, autoimmune regulator; Autoimmunity; CB-SCs, human cord blood-derived multipotent stem cells; CCR7, C–C chemokine receptor 7; Cord blood stem cell; HLA, human leukocyte antigen; HbA1C, glycated hemoglobin; IL, interleukin; Immune modulation; M2, muscarinic acetylcholine receptor 2; MLR, mixed leukocyte reactions; MNC, mononuclear cells; Memory T cells; OGTT, oral glucose tolerance test; PBMC, peripheral blood mononuclear cells; R, responder; S, stimulator; SCE, Stem Cell Educator; T1D, type 1 diabetes; TCM, central memory T cells; TCR, T-cell receptor; TEM, effector memory T cells; TGF-β1, transforming growth factor-β1; Th, helper T cell; Tregs, regulatory T cells; Type 1 diabetes.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autoimmunity*
  • C-Peptide / blood
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / metabolism
  • Diabetes Mellitus, Type 1 / therapy
  • Female
  • Follow-Up Studies
  • Gene Expression
  • Humans
  • Immunologic Memory*
  • Immunomodulation*
  • Insulin-Secreting Cells / immunology
  • Insulin-Secreting Cells / metabolism
  • Islets of Langerhans / immunology
  • Islets of Langerhans / metabolism
  • Male
  • Middle Aged
  • Receptors, CCR7 / genetics
  • Receptors, CCR7 / metabolism
  • Stem Cell Transplantation*
  • Stem Cells / metabolism*
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism*
  • Treatment Outcome
  • Young Adult


  • C-Peptide
  • Receptors, CCR7

Associated data